Overview Selinexor Treatment of Refractory Myeloma Status: Completed Trial end date: 2019-07-26 Target enrollment: Participant gender: Summary This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only). Phase: Phase 2 Details Lead Sponsor: Karyopharm Therapeutics IncKaryopharm Therapeutics, IncTreatments: BB 1101BortezomibDexamethasoneDexamethasone 21-phosphateDexamethasone acetateLenalidomidePomalidomideProteasome Inhibitors